Anticuerpos alfa 5-beta 1 y sus usos

• Main Authors: BRAMS, PETER, SPROUL, TIM W, BENDER, STEVEN LEE, YANG, LAN, JIANG, XIN, CHEN, HAIBIN, HUANG, HAICHUN, CASPERSON, GERALD FRIES, DEVAUX, BRIGITTE, LI, GANG, YAMANAKA, MARK, HU-LOWE, DANA DAN, TOY, KRISTOPHER, TANAMACHI, DAWN M, WANG, JIANYING, NORTH, MICHAEL AIDAN, WICKMAN, GRANT
• Format: Patent
• Language: Spanish
• Published: 26.05.2014
• Subjects: CHEMISTRY; HUMAN NECESSITIES; HYGIENE; MEDICAL OR VETERINARY SCIENCE; METALLURGY; ORGANIC CHEMISTRY; PEPTIDES; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS

Un anticuerpo monoclonal aislado capaz de unirse a la integrina α5ß1 que comprende: (a) una región variable de la cadena pesada CDR1 que comprende la SEQ ID NO: 1; (b) una región variable de la cadena pesada CDR2 que comprende la SEQ ID NO: 2; (c) una región variable de la cadena pesada CDR3 que comprende la SEQ ID NO: 3; (d) una región variable de la cadena ligera CDR1 que comprende la SEQ ID NO: 4; (e) una región variable de la cadena ligera CDR2 que comprende la SEQ ID NO: 5; y (f) una región variable de la cadena ligera CDR3 que comprende la SEQ ID NO: 6. The present disclosure provides isolated monoclonal antibodies, particularly human monoclonal antibodies, or antigen binding portions thereof, that specifically bind to integrin ±5²1 with high affinity. Nucleic acid molecules encoding the antibodies of the disclosure, expression vectors, host cells and methods for expressing the antibodies of the disclosure are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies or antigen binding portions thereof are also provided. The disclosure also provides methods for treating various cancers using the anti-±5²1 antibodies or antigen binding portions thereof described herein.